Navigation Links
CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group
Date:9/12/2008

y dialing (706) 645-9291; the PIN access number is 64328875.

About Angina

There are currently 48-50 million angina prescriptions written annually in the largest five EU member countries (UK, Germany, France, Spain and Italy). Chronic angina is a serious and debilitating heart condition, usually associated with coronary artery disease and marked by repeated and sometimes unpredictable attacks of chest pain.

About Menarini

The Menarini Group is one of the largest privately owned pharmaceutical companies, and is headquartered in Florence, Italy. Menarini employs approximately 12,500 people, with a strong presence throughout Europe, CIS, Africa and in South and Central America. The company has expertise in successfully developing and commercializing in-licensed drug products from major companies in a broad range of therapeutic areas. The Group's total revenue exceeds euro 2.5 billion.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. CV Therapeutics Ltd. is the company's European subsidiary based in the United Kingdom.

CV Therapeutics' approved products in the United States include Ranexa(R) (ranolazine extended-release tablets), indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and Lexiscan(TM) (regadenoson) injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress.

Except for the historical information contained herein, the matters set forth in this press release, including statements as to research and development and commercialization of products, are forward-looking statements within the meaning of
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cell Therapeutics to Host Investor Day in Milan, Italy on Friday, October 3, 2008
2. Halozyme Therapeutics to Present at Upcoming Investor Conferences
3. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
4. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
5. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
6. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
7. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
8. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
9. Nile Therapeutics to Present at BioCenturys NewsMakers in the Biotech Industry Conference
10. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
11. Cell Therapeutics, Inc. Announces Reverse Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ - RepliCel Life Sciences ... medicine company focused on the development of autologous cell ... of the University of Calgary in conjunction with co-authors ... which further validates the company,s ongoing clinical research using ... of pattern baldness. The paper entitled " ...
(Date:12/22/2014)... 2014  ( www.competitivehealth.com ) — Competitive Health is ... review and advocacy service, has signed an agreement to ... discount health services marketplace. 63% of Americans ... they expected to pay. As part of an ongoing ... Savings is pleased to offer medical bill review and ...
(Date:12/22/2014)... Fertility Associates of Memphis has announced ... , a network of more than 20 contributing ... have fast access to a national pool of frozen ... Fertility Associates of Memphis is the only fertility clinic ... , Dr. William Kutteh , director of Fertility ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
Breaking Biology Technology:Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2
... ARAY ), a global leader in the field of ... Euan S.,Thomson, Ph.D., is scheduled to present at the ... Thursday, September 25, 2008 at 9:00 a.m.,EDT (6:00 a.m. ... be available online from the,investor relations page of the ...
... teamed with a decades-old drug to beat atherosclerotic plaques ... in St. Louis. , The scientists have found that ... of tiny blood vessels that feed arterial plaques. Their ... vessels from restarting their growth, which could shrink or ...
... Business Expected -, HOUSTON, Sept. 15 ... an initial assessment, its corporate,headquarters in Houston, TX ... However, the facility could remain without power ... operating out of its disaster recovery,facility., Cyberonics ...
Cached Biology Technology:Accuray Incorporated's CEO to Speak at UBS Global Life Sciences Conference 2Old and new therapies combine to tackle atherosclerosis 2Old and new therapies combine to tackle atherosclerosis 3Cyberonics Provides Update on Business Operations Following Hurricane Ike 2Cyberonics Provides Update on Business Operations Following Hurricane Ike 3
(Date:12/10/2014)... December 9, 2014   ... Platform   Jifflenow, ... scheduling solutions for business-to-business (B2B) events, today announced ... in mobile near-field communication (NFC), Bluetooth low energy ... (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate ...
(Date:12/3/2014)... 2, 2014 As part of our commitment ... is pleased to announce the release of a new ... collect the workforce data that they need. ... left by existing readers. Many such devices have serious ... modern technology. Older models force users to navigate numerous ...
(Date:11/21/2014)... 20, 2014   Atmel® Corporation (NASDAQ: ... and touch technology solutions, today launched the industry,s first ... the widest V cc range from 1.7V to ... faster I 2 C bus communication speeds, and are ... making them ideal for consumer, industrial, computer, and medical ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Inception Technologies to Release New Biometric Reader 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4
... Yurttas Beim, PhD, Founder and CEO of the ... in the genetics of female infertility, presented A Report ... Revolution at the Futures in Reproduction Conference at the ... spirit of inquiry personified by Nobel Prize winner Professor ...
... 14, 2012 A fast growing, flesh-eating fungus killed ... Mo., according to two new studies based on genomic ... the U.S. Centers for Disease Control and Prevention (CDC). ... by the fungus Apophysomyces , according to the ...
... At crucial points in the metabolism of all organisms, ... Factor P (EF-P, for short) takes center stage. What ... been elucidated by researchers at Ludwig-Maximilians-Universitt in Munich. ... of Microbiology at LMU, actually focused on how bacteria ...
Cached Biology News:Report from the front lines of personalized reproductive medicine revolution 2Report from the front lines of personalized reproductive medicine revolution 3Fungus responsible for 5 deaths in the wake of massive tornado 2Fungus responsible for 5 deaths in the wake of massive tornado 3Raising the blockade 2
Human Presenilin-2 NTF Affinity Purified Polyclonal Ab...
... Cryo/CryoPlus Inventory Racks for ... available with cardboard or stainless ... or 5ml cryo vials. ... racks available. Platform risers ...
... This volume provides excellent background information, detailed ... of major HIV proteins including: the HIV ... and protease. Expression of HIV proteins using ... assays; HIV/CD4 interactions; transient assays for Nef-induced ...
Monkey IL-2 ELISPOT Kit with white/opague microtiter plates...
Biology Products: